Inspire Medical Faces Securities Fraud Lawsuit Amid Stock Drop and Inventory Issues
In a significant turn of events, Inspire Medical Systems, Inc. (INSP) is facing a pending securities class action lawsuit amid a substantial stock price drop and allegations of concealed operational issues. Investors who have suffered losses in the company are being urged to act as the deadline for lead plaintiff status approaches.
Background of the Case
The national investor rights law firm Hagens Berman has flagged the ongoing lawsuit against Inspire Medical Systems, notifying investors who may have been affected. The complaint revolves around misleading claims made by the company’s executives regarding the launch of the Inspire V, which was designed for patients suffering from obstructive sleep apnea. The law firm is particularly interested in investors who acquired securities from August 6, 2024, to August 4, 2025, before the drastic stock drop.
The lawsuit, filed in the U.S. District Court for the District of Minnesota, contends that Inspire Medical misrepresented its operational readiness for the commercial rollout of the Inspire V, asserting that it was poised to commence full operations. However, the reality of the launch was clouded by undisclosed operational failures that led to a catastrophic guidance slash and a steep decline in stock value. The company saw its shares tumble by $42.04 each, a staggering 32.4% decline.
Allegations of Concealment
The lawsuit lists several critical points that were allegedly concealed from investors:
1. Medicare Billing Readiness: The necessary updates for Medicare claims processing only took effect on July 1, 2025, creating hurdles for treatment centers to bill for the procedures, which hindered early adoption of the new device.
2. Inventory Surplus: A significant surplus of the older Inspire IV device was held by customers and treatment centers, adversely affecting the demand for the new Inspire V product.
3. Insufficient Training: Many implanting centers reportedly had not completed essential training and onboarding processes necessary for using the new device.
These undisclosed factors contributed to the company's inability to meet its projected rollout schedule and revenue expectations, prompting management to revise their earnings per share guidance downward by more than 80%.
Implications for Investors
Reed Kathrein, the partner leading this investigation, emphasizes that the allegations suggest a priority of maintaining a favorable narrative over actual operational readiness. Such misrepresentations led to investor losses that could have been avoided.
If you are an investor who belongs to the affected class period, you are encouraged to contact Hagens Berman to explore your legal options and potential next steps. Investors can gather more information by visiting their dedicated case page.
What Can You Do?
Investors with substantial losses on their Inspire Medical investments are encouraged to take action before the firm’s upcoming lead plaintiff deadline on January 5, 2026. The firm is ready to discuss legal rights, taking a proactive approach to address grievances stemming from the alleged misconduct by Inspire Medical.
In situations like this, whistleblowers with confidential information regarding Inspire Medical can report their findings through the SEC Whistleblower program to potentially receive rewards. Each piece of information could be instrumental in strengthening the case against the company.
Hagens Berman has a rich history of championing investors’ rights and holding corporations accountable for their actions. Their dedication has resulted in over $2.9 billion recovered for clients in various cases. Investors and whistleblowers alike are urged to stay informed and engaged during this pivotal time in the case against Inspire Medical Systems, which could significantly impact its future operations and stock value.
Background of the Case
The national investor rights law firm Hagens Berman has flagged the ongoing lawsuit against Inspire Medical Systems, notifying investors who may have been affected. The complaint revolves around misleading claims made by the company’s executives regarding the launch of the Inspire V, which was designed for patients suffering from obstructive sleep apnea. The law firm is particularly interested in investors who acquired securities from August 6, 2024, to August 4, 2025, before the drastic stock drop.
The lawsuit, filed in the U.S. District Court for the District of Minnesota, contends that Inspire Medical misrepresented its operational readiness for the commercial rollout of the Inspire V, asserting that it was poised to commence full operations. However, the reality of the launch was clouded by undisclosed operational failures that led to a catastrophic guidance slash and a steep decline in stock value. The company saw its shares tumble by $42.04 each, a staggering 32.4% decline.
Allegations of Concealment
The lawsuit lists several critical points that were allegedly concealed from investors:
1. Medicare Billing Readiness: The necessary updates for Medicare claims processing only took effect on July 1, 2025, creating hurdles for treatment centers to bill for the procedures, which hindered early adoption of the new device.
2. Inventory Surplus: A significant surplus of the older Inspire IV device was held by customers and treatment centers, adversely affecting the demand for the new Inspire V product.
3. Insufficient Training: Many implanting centers reportedly had not completed essential training and onboarding processes necessary for using the new device.
These undisclosed factors contributed to the company's inability to meet its projected rollout schedule and revenue expectations, prompting management to revise their earnings per share guidance downward by more than 80%.
Implications for Investors
Reed Kathrein, the partner leading this investigation, emphasizes that the allegations suggest a priority of maintaining a favorable narrative over actual operational readiness. Such misrepresentations led to investor losses that could have been avoided.
If you are an investor who belongs to the affected class period, you are encouraged to contact Hagens Berman to explore your legal options and potential next steps. Investors can gather more information by visiting their dedicated case page.
What Can You Do?
Investors with substantial losses on their Inspire Medical investments are encouraged to take action before the firm’s upcoming lead plaintiff deadline on January 5, 2026. The firm is ready to discuss legal rights, taking a proactive approach to address grievances stemming from the alleged misconduct by Inspire Medical.
In situations like this, whistleblowers with confidential information regarding Inspire Medical can report their findings through the SEC Whistleblower program to potentially receive rewards. Each piece of information could be instrumental in strengthening the case against the company.
Hagens Berman has a rich history of championing investors’ rights and holding corporations accountable for their actions. Their dedication has resulted in over $2.9 billion recovered for clients in various cases. Investors and whistleblowers alike are urged to stay informed and engaged during this pivotal time in the case against Inspire Medical Systems, which could significantly impact its future operations and stock value.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.